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Introduction
Triple negative breast cancer (TNBC) represents an especially aggressive and hard to treat subtype. The current frontline clinical TNBC therapies are limited to cytotoxic chemotherapy with or without the anti-angiogenic agent (bevacizumab) (1) . However, preclinical success has been gained by synthetic lethality, targeting genome instability with poly-ADP-ribosepolymerase (PARP) inhibition in breast cancer cells which harbour genetic or epigenetic silencing of the homologous recombination (HR) pathway routinely via the DNA damage repair mediator BRCA1 (2) . Histone deacetylase inhibitors (HDACi) are a class of drugs, which mediate epigenetic control of gene expression profiles. This occurs via HDACi-mediated genome-wide hyperacetylation of histones, resulting in a reordering of the chromatin structure, increasing accessibility to DNA for either induction or repression of transcriptional complexes (3, 4) . Several studies have documented HDACi-mediated repression of DNA repair protein expression and associated HDACi-induced DNA damage in solid tumours, reviewed in Slingerland et al. (5) .
Structurally different HDACi have been purified from natural sources or synthetically developed, which can be divided into six classes based on their chemical structure; these include short chain fatty acids (valproic acid-VPA), hydroxamic acids (suberylinamide hydroxamic acid-SAHA), benzamides, cyclic tetrapeptides (romidepsin-ROMI), electrophilic ketines and a remaining class of inhibitors with miscellaneous structures. Here we compare the activity of the pan-HDAC inhibitor (SAHA), the class I and IIa HDAC inhibitor (VPA) and the HDAC1 and 2-specific inhibitor (ROMI) for their capacity to regulate DNA damage repair gene expression and hence sensitize TNBC to PARPi. Specific inhibition of HDAC1/2 has been shown to repress genes involved in non-homologous end joining (NHEJ) (6) , while inhibition of HDAC 9/10 represses expression of homologous recombination (HR) genes (7) . Several HDAC inhibitors have been shown to repress expression of several HR proteins including RAD51 via reduced recruitment of the transcription factor, E2F1 (8, 9) . There is a great deal of heterogeneity in the genome maintenance mechanisms in sporadic TNBC (10) . In addition to the epigenetic silencing of BRCA gene, other drivers of impaired HR have been identified in TNBC (11) . We hypothesize that repression of specific members of the HR pathway are required to sensitize aggressive TNBC to HDAC and PARP inhibition. We suggest that different HDACi have different efficacies in modulating expression of HR genes and that HDACi catalyzed epigenetic regulation of HR gene expression is an effective means to induce a BRCAness state, thus creating synthetic lethality with PARP inhibition.
Materials and Methods

Cell lines
MDA-MB-231, MDA-MB-436 were sourced from the American Type Culture Collection (ATCC) cell bank and were STI profiled and verified in our lab (Jan 2015) , while the matched
HCC1937-BRCA1
MUT and HCC1937-BRCA1 RECON have been authenticated and reported previously (12, 13) and subsequently verified for BRCA1 expression (Dec 2014).
HDACi and PARPi individual drug dose curves
A total of 5x10 4 Simultaneous HR and NHEJ "traffic light" assay.
All cell lines were engineered to express the traffic light reporter system to analyze the activation status of both NHEJ and HR (14) . In brief, cells were transfected with lentivial packaging of pCVL Traffic Light Reporter 1.1 Ef1a Puro, and selected for with puromycin.
Positive colonies were screened for integration using Taqman 
Combination drug dose curves
In a 48 well plate, 36 wells of 3x10 4 cells per well were incubated in presence of escalating doses up to ~IC20 of HDACi for 24 hours. The wells were then rinsed with fresh media and the cells further incubated in the presence of 2.5μM of ABT-888 or DMSO for 48 hours. The cells were harvested and fixed with 70% ethanol and analysed for cell cycle profile using propidium iodide and FACS. Plots were graphed using graph-pad prism and represent the mean +/-SEM of 4 independent experiments. 
Long-term colony assay
Immunoblotting
Protein lysates were prepared via whole cell lysis in ice-cold lysis buffer (150mM NaCl, 10mM
Tris-Cl pH 7.4, 5mM EDTA, 1% Triton X-100) supplemented with protease inhibitors (Leupeptin, Pepstatin and PMSF, Sigma Aldridge). Immunoblots were probed with anti-RAD51 (Santa Cruz Biotech), anti-PARP (Millipore), anti-PAR (BD Biosceinces), DNA-PK;P2609 (Cell Signaling) and anti-53BP1 (Bethyl), and with anti-Tubulin (Sigma) and anti-ß-Actin, (Sigma) as controls. Membranes were developed using fluorescent-labeled secondary 6 antibodies and visualized using the Odyssey system. Protein expression levels were determined by optical density versus actin loading controls using Image J software (NIH).
Immunofluorescence
Approximately 5x10 4 Figure 1C vs D, Table S1 ). MDA-MB-436 also displayed exquisite sensitivity to ROMI 0.9 μM ( Figure 1B ), most likely due to an additional RB1 homozygous mutation (c.607-608ins227) in the cell line which renders tumours sensitive to changes in acetylation and is an effective treatment for retinoblastoma (15) . We also analysed the response of the four cell lines to PARP inhibitor ABT-888 for 24 hours, and again found the BRCA1 mutant lines displayed higher sensitivity to PARPi compared to the BRCA1 competent cell lines ( Figure 1E ). We did not observe the 1000 fold enhanced sensitivity comparing MDA-MB-231 and MDA-MB-436 achieved by the van't Veer group using olapirib however our 9 fold sensitivity was at 48 hours not 15 days ( Figure 1E ) (16) .
HDAC inhibitors suppress homologous recombination activity in breast cancer cells independent of BRCA1 status.
To determine the effect of epigenetic changes mediated by HDACi on DNA repair pathways we utilized the "traffic light" dual reporter (TLR) assay. This assay provides simultaneous Figure 1K ). This suggests a continued reliance on NHEJ, which was not altered by reconstitution with exogenous BRCA1 ( Figure 1J vs 1K).
We confirmed HDACi-mediated repression of HR in MDA-MB-231 using the DR-GFP construct and ISCE enzyme as described (18) Our results correlated with several published studies in that HDACi is able to repress HR activity in breast cancer cells (19, 20) . In addition we observe a corresponding shift to activation of mutagenic-NHEJ. Interestingly we find that HDACi are able to further influence DNA repair in BRCA1 mutant cell lines despite having reduced cellular HR activity.
Cell growth response of BRCA1 wild-type and mutated TNBC lines to the combination of HDAC and PARP inhibition.
We analysed the ability of HDACi to sensitize TNBC to PARP inhibition through repression of HR. We performed dose curves of each HDACi (doses 0 to ~IC20) in combination with or without the PARP inhibitor, ABT-888 (2.5μM). Drug scheduling allowed HDACi-mediated epigenetic change over the first 24 hours followed by inhibition of DNA repair with PARPi for a further 48 hours ( To quantitatively measure the dose-escalation relationship of the drugs in combination for synergy (combination index), an effective calculation is the use of median-drug effect analysis (Table S2) . SAHA displayed synergy with ABT-888 at 2.5μM, however when the order of drug incubation was reversed (incubation with PARPi followed by HDACi) this synergy was not observed CI=1.251 ( Figure 2H , Table S2 To provide direct evidence that these genes are critical for the cooperative anti-breast cancer activity of HDACi and PARPi, we next evaluated whether we could restore VPA activity in combination with ABT-888 by knockdown of RAD51, FANCD2 or BARD1. Individual gene knockdown did not induce sensitivity ( Figure S2F-H) , only with depletion of all three genes did we achieve significant cell death 64.2% vs 6.9% (*p=0.0006) ( Figure 3C vs 3D) . Restoration of sensitivity translated to significant long-term inhibition of growth, inhibiting 83% colony formation (**p=0.003) ( Figure 3E ). Interestingly the RAD51/FANCD2 combination also displayed significant inhibition of colony formation, 37% inhibition compared to the drug combination alone (*p=0.008). Of the three genes, only RAD51 overexpression is significantly correlated with worse disease free survival in TNBC patients (p=0.049) ( Figure 3F ). VPA has been utilized in a Phase II clinical trial against castration-resistant prostate cancers, which demonstrated some encouraging results (28) 
Checkpoint activation is a key mechanism in resistance to HDACi and PARPi combination.
We observed that the MDA-MB-436 cells had reduced HR-mediated repair capacity and were generally less responsive to the combination therapy, which could be attributed to functional loss of BRCA1 (21) . We wanted to validate these results using the HCC1937 breast cancer cell.
HCC1937-BRCA1
MUT cell line displayed a slight enhanced G1 population fraction in response to SAHA and an increased polyploid population after the addition of PARPi ( Figure 4A ), which was also observed with ROMI and PARPi ( Figure 4C ). We confirmed enhanced multinucleation by immunofluorescence ( Figure S3 ). This was consistent with the assumption that mutant BRCA1 and loss of functional HR drives aberrant repair resulting in multinucleation. In contrast to the other HDACi, VPA (10μM ∼IC20) in combination with
PARPi induced a slight G1 arrest rather than increase in polyploid fraction ( Figure 4B ). This lack of enhanced polyploid population was also observed in the BRCA1 reconstituted Cell cycle arrest stifles this mechanism and can in-part provide an explanation for lack of PARP activity, while loss of PTEN is thought to inhibit response (21) . The observed G1 arrest in response to ROMI in cells with reconstituted BRCA1 (Figure 4F ) is readily accounted for by the changes in gene expression including BARD1 a ubiquitin ligase that binds BRCA1 and regulates cell cycle and DNA repair, CHEK1 a cell cycle kinase that regulates checkpoint arrest and FANCD2 that controls chromosome stability ( Figure 4J ). Of note BRCA1 expression was increased validating the cell line genetics (Fig 4J) . Interestingly a similar arrest was observed in MDA-MB-436 in response to ROMI, suggesting a greater role for the aforementioned BARD1, CHEK1 and FANCD2 genes ( Figure 2G ). In contrast, the absence of functional BRCA1 in BRCA1 MUT cells meant 18% progressed through mitosis to a polyploidy state in the presence of ROMI ( Figure 4C ) and were unable to form colonies ( Figure 4H ). In this case we observed 
Treatment of HCC1937-BRCA1
MUT with ROMI and ABT-888 resulted in an enhanced polyploidy/multinucleation population ( Figure 4C ). This phenomenon was not observed in
, most likely related to reduced HR activity ( Figure 1K ) and was similar to that seen in MDA-MB-231 (Fig 1I) . To examine whether this polyploid population contributed to the small resistant population observed in colony assays ( Figure 4G ), we sorted the polyploid population post treatment ( Figure 5A ), confirmed multinucleated cells ( Figure   S3 ) and compared growth rate to unsorted cells. The polyploidy purified population only achieved 5% growth over 5 days compared to over 20% for unsorted cells ( Figure 5B ).
Comparison of the purified polyploid population to untreated and unsorted populations for sensitivity to ROMI and ABT-888 revealed that the sorted population retained similar sensitivity as unsorted cells to ROMI but displayed increased resistance to ABT-888, but not to the level afforded by BRCA1 reconstitution (Table 1) . Protein expression analysis revealed no corresponding increase in FANCD2, BARD1 or PARP1 but enhanced RAD51 expression in the polyploid population ( Figure 5C ), which was confirmed by intracellular FACS staining in all cell lines ( Figure 5D ). This suggests that RAD51 contributes to survival of the polyploid population and resistance to PARPi. To confirm that RAD51 contributes to PARPi resistance we overexpressed RAD51 in the low RAD51 expressing breast cancer cell line Hs578t ( Figure   5E ). Increased expression of RAD51 independent of PARP1 expression increased IC50 of ABT-888 3.9 fold from 15.2μM vs 59.1μM ( Figure 5F ). Taken together the results suggest that after treatment with the combination of HDACi and PARPi, BRCA1-deficient cells initially survive by upregulating RAD51 expression and bypassing cell cycle arrest resulting in polyploidy. However these cells display no sustained survival, which could be due to lack of BARD1 and/or FANCD2 expression. 
Discussion
The observation that HDACis suppress multiple DNA damage response pathways including HR creates the opportunity for synthetic lethality in solid cancers. In vivo studies have demonstrated that the combination of ABT-888 and SAHA is able to retard growth of established MDAM-MB-231 xenografts (19) . There are several current ongoing clinical trials utilizing the HDACis we studied including; a pilot study for SAHA against TNBC (NCT01695057) and phase I trial with a ROMI and cisplatin combination against breast cancer (NCT02393794) and phase II trial with VPA against breast cancer. There is also a recently terminated phase II trial with VPA against breast cancer (NCT00395655). This trial could have benefitted from our potential biomarkers of resistance to VPA namely BARD1, FANCD2 and RAD51. In addition another key clinical marker for HDAC activity is the observed shift in from HR to mutagenic-NHEJ activity (30) . This creates the conditions required for PARP inhibition-mediated synthetic lethality and a rationale for use of HDACi to create an epigenetic-mediated BRCAness via downregulation of key HR gene expression. We observed the requirement for down regulation of RAD51, BARD1 and FANCD2 expression for effective HDAC inhibitor activity and a role for RAD51 in mechanisms of resistance to PARP inhibition-induced polyploidy. Therefore we suggest that RAD51 expression is a key regulator of synthetic lethality.
RAD51 is a key protein in the final steps of HR and functions to bind the resected ssDNA and search for the complementary sequence on the sister chromatid, resulting in high fidelity repair.
The expression of RAD51 is known to be upregulated in BRCA1-deficient tumours compensating for the loss of HR, allowing carcinogenic progression and metastasis (31) .
Inhibition of RAD51 has been found to synergize with inhibition of PARP in both RNA knockdown screens and small molecule screens (32) (33) (34) . Our study supports these observations with RAD51 overexpression enhancing resistance to PARPi. Further we showed that the PARPi-resistant polyploid population displayed increased expression of RAD51. This suggests that RAD51 is a driver of aberrant recombination suggesting a mechanism for cell survival.
Indeed overexpression of RAD51 in normal cells drives pathological recombination events such as chromosomal amplifications, deletions and translocations resulting in loss of heterozygosity and aneuploidy (35) . Lack of suppression of RAD51 expression in the presence of VPA might explain the observed resistance to PARPi, however depletion of RAD51 alone was not enough to restore activity and required co-operative loss of FANCD2 for significance. 
These findings suggest that inherently unstable genomes are stabilized by RAD51 expression as a mechanism for cell survival, which can infer resistance to PARP inhibition.
In the breast cancer setting increased expression of FANCD2 is associated with high proliferation rates and replication stress (36) and associates with BRCA1 and RAD51 at sites of DNA damage to guarantee the integrity of genome during replication (37, 38) . Interestingly in a panel of 1240 paraffin-embedded breast tumors, overexpression of FANCD2 was shown to be prognostic for poor patient survival whereas RAD51 was not (39) . However this observation was in hormone receptor positive breast cancer, whereas RAD51 has been associated with poorer prognosis in TNBC (29). BRCA1/BARD1 complex is known to regulate FANCD2 via monoubiquitination, however we observe a transcriptional upregulation of FANCD2 after BRCA1 reconstitution in HCC1937 cells. BRCA1 has auto-transcriptional activity but can also be regulated by E2F1, a transcription factor shared with FANCD2 hinting at a role for E2F1 in resistance to DNA-damage induced cell death. The transcriptional mechanism by which FANCD2 is regulated is yet to be fully delineated. We speculate that BRCA1 could act as a transcriptional co-factor to induce FANCD2 expression, which could contribute to resistance to PARPi. Of note FANCD2 upregulation has indeed been associated with HDAC and PARP inhibition resistant hepatocellular carcinoma cells (40) and recently complementation of BRCA1 deficient cell lines with FANCD2 was shown to restore normal HR function (41) . We suggest that RAD51 is the main contributor to PARPi resistance as the depletion of RAD51 has been shown to be more potent than that of FANCD2 in sensitizing HeLa cells to PARPi (34) .
Along with RAD51 and FANCD2, loss of BARD1 expression was required to sensitize BRCA1 competent cells to combination of VPA and PARPi. BARD1 facilitates BRCA1 nuclear translocation for DNA repair and enhances DNA binding. Upon DNA damage BARD1/BRCA1 heterodimers form nuclear foci in complexes that can include BRCA2 and RAD51 (42) , which directs HR-mediated repair via the BRCA1-BRCA2 linker protein PALB2 (43) . Of importance is the observation that HDACi-mediated stabilization of mutant BRCA1 protein via hyperacetylation of Hsp90 (19) , can enhance resistance to PARPi via stabilization of BRCA1/BARD1 -PALB2-BRCA2/RAD51 complexes (44) . This could account for our observed reduced efficacy of the HDACi/PARPi combination in BRCA1 mutant cells in short term assays. However alternate studies demonstrate that loss of PTEN is the main mechanism for resistance to SAHA and PARPi in TNBC (21) . This could be true for MDA-MB-436, which harbors a PTEN mutation, however we were able to induce cell death in HCC1937 that also 
